Neurocrine plans to sell shares
Biotechnology company Neurocrine Biosciences Inc. said on Thursday that it plans to sell shares in an underwritten public offering.
The book-runner will be Jefferies & Co.
The size and pricing for the offering have not yet been set. Neurocrine shares fell 3 cents to close at $2.60 on Thursday.